The Battle Of Blockbuster Heart Drugs
Confused by competing claims for the newest of the cholesterol-lowering drugs? You're not alone. Bristol-Myers Squibb Co.'s pravastatin, sold as Pravachol, and Merck & Co.'s simvastatin, or Zocor, offer a revolutionary approach to combating heart disease, the nation's No.1 killer. They are locked in a fierce battle over a market estimated at $6.5 billion.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.